Outcomes
The primary endpoint was to determine the recommended phase II dose (RP2D) for irinotecan in combination with veliparib. Secondary endpoints were to determine the pharmacokinetic profile of veliparib and irinotecan and to determine the overall response rate by RECIST v1.1.